Functional genomics of cancer

Current Opinion in Genetics and Development

Volumn 18, Issue 3, 2008, Pages 251-256

  Liu, Edison T ^a  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; BORTEZOMIB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; PROTEOME; TOPOTECAN; TRANSCRIPTOME;

ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER GENETICS; CANCER RESISTANCE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMATIN; COLON CANCER; COLORECTAL CANCER; DNA BINDING; DNA METHYLATION; DNA SEQUENCE; DRUG EFFECT; FUNCTIONAL GENOMICS; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; HUMAN; MISSENSE MUTATION; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; NEOPLASM; NONSENSE MUTATION; ONCOGENE C MYC; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REGULATORY MECHANISM; REVIEW;

ANIMALS; COMPUTATIONAL BIOLOGY; GENE REGULATORY NETWORKS; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; GENOMICS; HUMANS; NEOPLASMS;

EID: 52949083552     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2008.07.014     Document Type: Review

References (39)

1. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., Cronin M., Baehner F.L., Watson D., Bryant J., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 August (23) (2006) 3726-3734. This paper and the next are among the first to validate commercial diagnostic arising from array-based expression genomic studies in large clinical studies paving the way for clinical use of these products in the primary care of cancer patients.
2. Buyse M., Loi S., van't Veer L., Viale G., Delorenzi M., Glas A.M., d'Assignies M.S., Bergh J., Lidereau R., Ellis P., et al. TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98 September (17) (2006) 1183-1192. As noted above.
3. Potti A., Mukherjee S., Petersen R., Dressman H.K., Bild A., Koontz J., Kratzke R., Watson M.A., Kelley M., Ginsburg G.S., et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355 August (6) (2006) 570-580
4. Ivshina A.V., George J., Senko O., Mow B., Putti T.C., Smeds J., Lindahl T., Pawitan Y., Hall P., et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66 (2006) 10292-10301
5. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., Nordgren H., Farmer P., Praz V., Haibe-Kains B., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 (2006) 262-272
6. Sotiriou C., and Piccart M.J. Taking gene expression pofiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 7 July (2007) 545-552
7. Tomlins S.A., Mehra R., Rhodes D.R., Cao X., Wang L., Dhanasekaran S.M., Kalyana-Sundaram S., Wei J.T., Rubin M.A., Pienta K.J., et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39 January (1) (2007) 41-51. Using a clever application of an informatics mining approach, Arul Chinnaiyan's group identified transcriptional modules that might be drivers for prostate cancer progression.
8. Wong D.J., Liu H., Ridky T.W., Cassarino D., Segal E., and Chang H.Y. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2 April (4) (2008) 333-344
9. Hanna J., Markoulaki S., Schorderet P., Carey B.W., Beard C., Wernig M., Creyghton M.P., Steine E.J., Cassady J.P., Foreman R., et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 133 April (2) (2008) 250-264
10. Lowry W.E., Richter L., Yachechko R., Pyle A.D., Tchieu J., Sridharan R., Clark A.T., and Plath K. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A 105 February (8) (2008) 2883-2888
11. Wong D.J., Nuyten D.S., Regev A., Lin M., Adler A.S., Segal E., van de Vijver M.J., and Chang H.Y. Revealing targeted therapy for human cancer by gene module maps. Cancer Res 68 January (2) (2008) 369-378
12. Acharya C.R., Hsu D.S., and Anders C.K. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA 299 13 (2008) 1574-1587
13. Brock M.V., Hooker C.M., Ota-Machida E., Han Y., Guo M., Ames S., Glöckner S., Piantadosi S., Gabrielson E., Pridham E., et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358 March (11) (2008) 1118-1128
14. Jones P.A., and Baylin S.B. The epigenomics of cancer. Cell 128 (2007) 683-692
15. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E., et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39 February (2) (2007) 232-236. This is among the first descriptions of the linkage between H3K27 methylation and DNA methylation in cancer.
16. Ding L., and Kleer C.G. Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res 66 October (19) (2006) 9352-9355
17. Yu J., Cao Q., Mehra R., Laxman B., Yu J., Tomlins S.A., Creighton C.J., Dhanasekaran S.M., Shen R., Chen G., et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 12 November (5) (2007) 419-431
18. Yu J., Yu J., Rhodes D.R., Tomlins S.A., Cao X., Chen G., Mehra R., Wang X., Ghosh D., Shah R.B., et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 67 November (22) (2007) 10657-10663
19. Tan J., Yang X., Zhuang L., Jiang X., Chen W., Lee P.L., Karuturi R.K., Tan P.B., Liu E.T., and Yu Q. Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21 May (9) (2007) 1050-1063. This work identifies a small molecular, DZNep that appears to interrupt the PRC2 complex responsible for H3K27 methylation. Targeting the PRC2 complex for downregulation, these investigators show that DZNep has anti-cancer effect.
20. •] showing that the combination of DZNep and an HDAC inhibitor is highly synergistic in inducing apoptosis in cancer cells. This apoptosis is mediated through the downregulation of the WNT pathway through induction of a natural WNT inhibitor, DACT3.
21. Marcucci G., Radmacher M.D., Maharry K., Mrózek K., Ruppert A.S., Paschka P., Vukosavljevic T., Whitman S.P., Baldus C.D., and Langer C. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 358 May (18) (2008) 1919-1928
22. Bommer G.T., Gerin I., Feng Y., Kaczorowski A.J., Kuick R., Love R.E., Zhai Y., Giordano T.J., Qin Z.S., Moore B.B., et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17 August (15) (2007) 1298-1307
23. Corney D.C., Flesken-Nikitin A., Godwin A.K., Wang W., and Nikitin A.Y. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67 September (18) (2007) 8433-8438
24. •] (see below) are among the most complete in their analysis.
25. Tazawa H., Tsuchiya N., Izumiya M., and Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A 104 September (39) (2007) 15472-15477
26. Tarasov V., Jung P., Verdoodt B., Lodygin D., Epanchintsev A., Menssen A., Meister G., and Hermeking H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6 July (13) (2007) 1586-1593. As noted above.
27. He L., He X., Lim L.P., de Stanchina E., Xuan Z., Liang Y., Xue W., Zender L., Magnus J., Ridzon D., et al. A microRNA component of the p53 tumour suppressor network. Nature 447 June (7148) (2007) 1130-1134. As noted above.
28. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., Feldmann G., Yamakuchi M., Ferlito M., Lowenstein C.J., et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26 June (5) (2007) 745-752
29. Sjöblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 October (5797) (2006) 268-274. One of the first landmark papers on the comprehensive sequencing of exons in breast and colon cancers. Their results show that mutations are common but appear to be widely distributed.
30. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., et al. Patterns of somatic mutation in human cancer genomes. Nature 446 March (7132) (2007) 153-158. This is the second landmark paper describing the sequencing of all kinases in a much larger number of primary cancers and again showed the distributed nature of mutations but identified a number of pathways more frequently mutated than others.
31. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 October (5748) (2005) 644-648. This is a landmark paper that described the identification of a recurrent fusion transcript that predominates in prostate cancer. Methodologically, it represents an intelligent application of a combination of informatics, molecular biology, and translational sciences to prove the underlying hypothesis.
32. ••]) that describes the mechanism of activation induced by the various ETS translocations in prostate cancer.
33. •]) uses two different strategies to identify putative translocations/rearrangements in cancer cell lines. Taken together, the estimate for high probability fusion transcripts per cell line is between 30 and 100.
34. Campbell P.J., Stephens P.J., Pleasance E.D., O'Meara S., Li H., Santarius T., Stebbings L.A., Leroy C., Edkins S., Hardy C., et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 40 June (6) (2008) 722-729. As above.
35. Amit I., Citri A., Shay T., Lu Y., Katz M., Zhang F., Tarcic G., Siwak D., Lahad J., and Jacob-Hirsch J. A module of negative feedback regulators defines growth factor signaling. Nat Genet 39 April (4) (2007) 503-512
36. Pujana M.A., Han J.D., Starita L.M., Stevens K.N., Tewari M., Ahn J.S., Rennert G., Moreno V., Kirchhoff T., and Gold B. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 39 November (11) (2007) 1338-1349
37. Cox A., Dunning A.M., Garcia-Closas M., Balasubramanian S., Reed M.W., Pooley K.A., Scollen S., Baynes C., Ponder B.A., Chanock S., et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39 March (3) (2007) 352-358
38. Easton D.F., Pooley K.A., Dunning A.M., Pharoah P.D., Thompson D., Ballinger D.G., Struewing J.P., Morrison J., Field H., Luben R., et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447 June (7148) (2007) 1087-1093
39. Garcia-Closas M., Hall P., Nevanlinna H., Pooley K., Morrison J., Richesson D.A., Bojesen S.E., Nordestgaard B.G., Axelsson C.K., Arias J.I., et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 4 April (4) (2008) e1000054